CLINICAL TRIALS PROFILE FOR PAROEX

All Clinical Trials for PAROEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Dr. August Wolff GmbH & Co. KG Arzneimittel	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Gaba International AG	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Heidelberg University	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.

Clinical Trial Conditions for PAROEX

Condition Name

Condition Name for PAROEX
Intervention	Trials
Periodontitis	2
Diabetes Mellitus, Type II	1

Condition MeSH

Condition MeSH for PAROEX
Intervention	Trials
Periodontitis	2
Diabetes Mellitus, Type 2	1
Diabetes Mellitus	1

Clinical Trial Locations for PAROEX

Trials by Country

Trials by Country for PAROEX
Location	Trials
United States	1
Germany	1

Trials by US State

Trials by US State for PAROEX
Location	Trials
New York	1

Clinical Trial Progress for PAROEX

Clinical Trial Phase

Clinical Trial Phase for PAROEX
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for PAROEX
Clinical Trial Phase	Trials
Completed	1
Terminated	1

Clinical Trial Sponsors for PAROEX

Sponsor Name

Sponsor Name for PAROEX
Sponsor	Trials
Sunstar, Inc.	1
State University of New York at Buffalo	1
Dr. August Wolff GmbH & Co. KG Arzneimittel	1

Sponsor Type

Sponsor Type for PAROEX
Sponsor	Trials
Industry	3
Other	3